Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy

Journal of Virology

Volumn 84, Issue 8, 2010, Pages 3835-3844

  Elankumaran, Subbiah ^a   Chavan, Vrushali ^a   Qiao, Dan ^a   Shobana, Raghunath ^a   Moorkanat, Gopakumar ^a   Biswas, Moanaro ^a   Samal, Siba K ^b  

^a CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON REGULATORY FACTOR 7; VIRUS PROTEIN V; 36 KDA V PROTEIN, NEWCASTLE DISEASE VIRUS; INTERFERON; ONCOLYTIC VIRUS; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL KILLING; CONTROLLED STUDY; FIBROSARCOMA; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DISEASE MODEL; DRUG ANTAGONISM; GENETIC RECOMBINATION; GENETICS; IMMUNOLOGY; METHODOLOGY; NUDE MOUSE; PATHOLOGY;

AVES; MUS; MUS MUSCULUS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; FIBROSARCOMA; HUMANS; INTERFERON TYPE I; MICE; MICE, INBRED BALB C; MICE, NUDE; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECOMBINATION, GENETIC; VIRAL PROTEINS;

EID: 77950482295     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01553-09     Document Type: Article

References (46)

1. Advani, A. S., and A. M. Pendergast. 2002. Bcr-Abl variants: biological and clinical aspects. Leukoc. Res. 26: 713-720.
2. Arora, T., G. Floyd-Smith, M. J. Espy, and D. F. Jelinek. 1999. Dissociation between IFN-alpha-induced anti-viral and growth signaling pathways. J. Immunol. 162: 3289-3297.
3. Bell, S., S. Hansen, and J. Buchner. 2002. Refolding and structural characterization of the human p53 tumor suppressor protein. Biophys. Chem. 96: 243-257.
4. Bello, M. J., J. M. de Campos, M. E. Kusak, J. Vaquero, J. L. Sarasa, A. Pestana, and J. A. Rey. 1994. Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9: 296-298. (Pubitemid 24114835)
5. Bian, H., P. Fournier, B. Peeters, and V. Schirrmacher. 2005. Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein. Int. J. Oncol. 27: 377-384.
6. Cassel, W. A., and D. R. Murray. 1992. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med. Oncol. Tumor Pharmacother. 9: 169-171.
7. Csatary, L. K. 1971. Viruses in the treatment of cancer. Lancet ii: 825.
8. Dong, B., and R. H. Silverman. 1997. A bipartite model of 2-5A-dependent RNase L. J. Biol. Chem. 272: 22236-22242.
9. Elankumaran, S., D. Rockemann, and S. K. Samal. 2006. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 80: 7522-7534.
10. Fiola, C., B. Peeters, P. Fournier, A. Arnold, M. Bucur, and V. Schirrmacher. 2006. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int. J. Cancer 119: 328-338.
11. Freeman, A. I., Z. Zakay-Rones, J. M. Gomori, E. Linetsky, L. Rasooly, E. Greenbaum, S. Rozenman-Yair, A. Panet, E. Libson, C. S. Irving, E. Galun, and T. Siegal. 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13: 221-228.
12. Gromeier, M., and E. Wimmer. 2001. Viruses for the treatment of malignant glioma. Curr. Opin. Mol. Ther. 3: 503-508.
13. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
14. Honda, K., H. Yanai, A. Takaoka, and T. Taniguchi. 2005. Regulationofthe type I IFN induction: a current view. Int. Immunol. 17: 1367-1378.
15. Hrabak, A., I. Csuka, T. Bajor, and L. K. Csatary. 2006. The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro. Cancer Lett. 231: 279-289.
16. Huang, Z., S. Krishnamurthy, A. Panda, and S. K. Samal. 2003. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J. Virol. 77: 8676-8685.
17. Huang, Z., A. Panda, S. Elankumaran, D. Govindarajan, D. D. Rockemann, and S. K. Samal. 2004. The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J. Virol. 78: 4176-4184. (Pubitemid 38437223)
18. Ito, Y., Y. Nagai, and K. Maeno. 1982. Interferonproductioninmouse spleen cells and mouse fibroblasts (L cells) stimulated by various strains of Newcastle disease virus. J. Gen. Virol. 62: 349-352.
19. Kasuya, H., Y. Nishiyama, S. Nomoto, F. Goshima, S. Takeda, I. Watanabe, N. Nomura, T. Shikano, T. Fujii, N. Kanazumi, and A. Nakao. 2007. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther. 14: 533-542.
20. Kerr, I. M., and R. E. Brown. 1978. pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferontreated cells. Proc. Natl. Acad. Sci. U. S. A. 75: 256-260.
21. Khuri, F. R., J. Nemunaitis, I. Ganly, J. Arseneau, I. F. Tannock, L. Romel, M. Gore, J. Ironside, R. H. MacDougall, C. Heise, B. Randlev, A. M. Gillenwater, P. Bruso, S. B. Kaye, W. K. Hong, and D. H. Kirn. 2000. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6: 879-885.
22. Krishnamurthy, S., Z. Huang, and S. K. Samal. 2000. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278: 168-182.
23. Krishnamurthy, S., T. Takimoto, R. A. Scroggs, and A. Portner. 2006. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J. Virol. 80: 5145-5155.
24. Kruyt, F. A., and D. T. Curiel. 2002. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum. Gene Ther. 13: 485-495.
25. Lana, D. P., D. B. Snyder, D. J. King, and W. W. Marquardt. 1988. Characterization of a battery of monoclonal antibodies for differentiation of Newcastle disease virus and pigeon paramyxovirus-1 strains. Avian Dis. 32: 273-281.
26. Li, H. O., Y. F. Zhu, M. Asakawa, H. Kuma, T. Hirata, Y. Ueda, Y. S. Lee, M. Fukumura, A. Iida, A. Kato, Y. Nagai, and M. Hasegawa. 2000. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. 74: 6564-6569.
27. Lorence, R. M., B. B. Katubig, K. W. Reichard, H. M. Reyes, A. Phuangsab, M. D. Sassetti, R. J. Walter, and M. E. Peeples. 1994. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 54: 6017-6021. (Pubitemid 24378619)
28. Lorence, R. M., A. L. Pecora, P. P. Major, S. J. Hotte, S. A. Laurie, M. S. Roberts, W. S. Groene, and M. K. Bamat. 2003. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 5: 618-624.
29. Lorence, R. M., K. W. Reichard, B. B. Katubig, H. M. Reyes, A. Phuangsab, B. R. Mitchell, C. J. Cascino, R. J. Walter, and M. E. Peeples. 1994. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst. 86: 1228-1233. (Pubitemid 24253698)
30. Lorence, R. M., P. A. Rood, and K. W. Kelley. 1988. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J. Natl. Cancer Inst. 80: 1305-1312.
31. Lu, X., T. Nikaido, T. Toki, Y. L. Zhai, N. Kita, I. Konishi, and S. Fujii. 2000. Loss of heterozygosity among tumor suppressor genes in invasive and in situ carcinoma of the uterine cervix. Int. J. Gynecol. Cancer 10: 452-458.
32. Martin, K. J., E. Graner, Y. Li, L. M. Price, B. M. Kritzman, M. V. Fournier, E. Rhei, and A. B. Pardee. 2001. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc. Natl. Acad. Sci. U. S. A. 98: 2646-2651.
33. Meurs, E. F., Y. Watanabe, S. Kadereit, G. N. Barber, M. G. Katze, K. Chong, B. R. Williams, and A. G. Hovanessian. 1992. Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. J. Virol. 66: 5805-5814.
34. Pecora, A. L., H. M. Lazarus, A. A. Jennis, R. A. Preti, S. L. Goldberg, S. D. Rowley, S. Cantwell, B. W. Cooper, E. A. Copelan, R. H. Herzig, R. Meagher, M. J. Kennedy, L. R. Akard, J. Jansen, A. Ross, M. Prilutskaya, J. Glassco, D. Kahn, and T. J. Moss. 2002. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol. Blood Marrow Transplant. 8: 536-543.
35. Pecora, A. L., N. Rizvi, G. I. Cohen, N. J. Meropol, D. Sterman, J. L. Marshall, S. Goldberg, P. Gross, J. D. O'Neil, W. S. Groene, M. S. Roberts, H. Rabin, M. K. Bamat, and R. M. Lorence. 2002. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20: 2251-2266.
36. Phuangsab, A., R. M. Lorence, K. W. Reichard, M. E. Peeples, and R. J. Walter. 2001. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 172: 27-36.
37. Reichard, K. W., R. M. Lorence, C. J. Cascino, M. E. Peeples, R. J. Walter, M. B. Fernando, H. M. Reyes, and J. A. Greager. 1992. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 2: 448-453.
38. Samuel, M. A., K. Whitby, B. C. Keller, A. Marri, W. Barchet, B. R. Williams, R. H. Silverman, M. Gale, Jr., and M. S. Diamond. 2006. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 80: 7009-7019.
39. Sato, M., N. Hata, M. Asagiri, T. Nakaya, T. Taniguchi, and N. Tanaka. 1998. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441: 106-110.
40. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67: 227-264.
41. Stojdl, D. F., B. Lichty, S. Knowles, R. Marius, H. Atkins, N. Sonenberg, and J. C. Bell. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6: 821-825.
42. Stojdl, D. F., B. D. Lichty, B. R. tenOever, J. M. Paterson, A. T. Power, S. Knowles, R. Marius, J. Reynard, L. Poliquin, H. Atkins, E. G. Brown, R. K. Durbin, J. E. Durbin, J. Hiscott, and J. C. Bell. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
43. Tikhonov, S. N., K. A. Rotov, N. P. Khrapova, V. V. Alekseev, E. A. Snatenkov, A. A. Zamarin, and N. A. Simakova. 2008. Effect of liposomal tetracycline hydrochloride on enzymatic function of the liver. Bull. Exp. Biol. Med. 145: 443-445.
44. Vigil, A., M. S. Park, O. Martinez, M. A. Chua, S. Xiao, J. F. Cros, L. Martinez-Sobrido, S. L. Woo, and A. Garcia-Sastre. 2007. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67: 8285-8292.
45. Williams, B. R. 1991. Transcriptional regulation of interferon-stimulated genes. Eur. J. Biochem. 200: 1-11.
46. Zamarin, D., A. Vigil, K. Kelly, A. Garcia-Sastre, and Y. Fong. 2009. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 16: 796-804.